Prostate cancer can sometimes be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney (Dana-Farber Cancer Institute), will cut the time required to assess new targeted drug therapies for aggressive prostate cancer by 50%.

Dr. Sweeney and his team identified a new set of clinical trial endpoints that will shorten the time taken to conduct clinical trials and present finding to the FDA. The new “big data” analysis in over 20,000 patients, enables the development of novel therapies that can be administered at the earliest—and potentially most curative—stage possible.

Story #1

Checkpoint Immunotherapy CAN Work Exceptionally in Prostate Cancer

Please consider donating to further research in 2017.